Laura Senovilla

List of Publications by Year
in descending order

80	8,568	53794 45	66911 78
papers	citations	h-index	g-index

81	81	81	14849
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In Vivo Imaging of Orthotopic Lung Cancer Models in Mice. Methods in Molecular Biology, 2021, 2279, 199-212.	0.9	5
2	Clonogenic Assays to Detect Cell Fate in Mitotic Catastrophe. Methods in Molecular Biology, 2021, 2267, 227-239.	0.9	3
3	Quantification of eIF2Î± Phosphorylation Associated with Mitotic Catastrophe by Immunofluorescence Microscopy. Methods in Molecular Biology, 2021, 2267, 217-226.	0.9	2
4	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death and Disease, 2021, 12, 978.	6.3	9
5	Paradoxical implication of BAX/BAK in the persistence of tetraploid cells. Cell Death and Disease, 2021, 12, 1039.	6.3	7
6	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	12.8	71
7	Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. OncoImmunology, 2019, 8, e1656502.	4.6	45
8	Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. OncoImmunology, 2019, 8, 1657374.	4.6	36
9	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	12.8	189
10	eIF2Î± phosphorylation is pathognomonic for immunogenic cell death. Cell Death and Differentiation, 2018, 25, 1375-1393.	11.2	162
11	Calcium signaling and cell cycle: Progression or death. Cell Calcium, 2018, 70, 3-15.	2.4	152
12	Immune effectors responsible for the elimination of hyperploid cancer cells. OncoImmunology, 2018, 7, e1463947.	4.6	14
13	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunological Reviews, 2017, 280, 165-174.	6.0	82
14	Image Cytofluorometry for the Quantification of Ploidy and Endoplasmic Reticulum Stress in Cancer Cells. Methods in Molecular Biology, 2017, 1524, 53-64.	0.9	8
15	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell, 2016, 30, 147-160.	16.8	410
16	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. OncoImmunology, 2016, 5, e1160193.	4.6	11
17	Positive impact of autophagy in human breast cancer cells on local immunosurveillance. OncoImmunology, 2016, 5, e1174801.	4.6	10
18	The ratio of CD8⁺/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. OncoImmunology, 2016, 5, e1218106.	4.6	50

#	Article	IF	Citations
19	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. OncoImmunology, 2016, 5, e1139275.	4.6	21
20	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy, 2016, 12, 864-875.	9.1	90
21	eIF2Î± phosphorylation as a biomarker of immunogenic cell death. Seminars in Cancer Biology, 2015, 33, 86-92.	9.6	95
22	Karyotypic Aberrations in Oncogenesis and Cancer Therapy. Trends in Cancer, 2015, 1, 124-135.	7.4	28
23	Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine, 2015, 21, 1128-1138.	30.7	268
24	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy, 2015, 11, 1878-1890.	9.1	91
25	Morphometric analysis of immunoselection against hyperploid cancer cells. Oncotarget, 2015, 6, 41204-41215.	1.8	13
26	Chemosensitization strategies for the treatment of lung cancer. Oncoscience, 2015, 2, 833-834.	2.2	0
27	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
28	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
29	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. OncoImmunology, 2014, 3, e28473.	4.6	112
30	Coffee induces autophagy in vivo. Cell Cycle, 2014, 13, 1987-1994.	2.6	49
31	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. OncoImmunology, 2014, 3, e955685.	4.6	16
32	Regulation of Autophagy by Cytosolic Acetyl-Coenzyme A. Molecular Cell, 2014, 53, 710-725.	9.7	412
33	Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3020-3025.	7.1	59
34	Impact of myeloid cells on the efficacy of anticancer chemotherapy. Current Opinion in Immunology, 2014, 30, 24-31.	5.5	35
35	Immunogenic cell death inducers as anticancer agents. Oncotarget, 2014, 5, 5190-5191.	1.8	67
36	Immunosurveillance as a regulator of tissue homeostasis. Trends in Immunology, 2013, 34, 471-481.	6.8	50

#	Article	IF	Citations
37	Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. Annals of the New York Academy of Sciences, 2013, 1284, 57-61.	3.8	7
38	Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. Autophagy, 2013, 9, 415-417.	9.1	48
39	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle, 2013, 12, 877-883.	2.6	57
40	Crosstalk between ER stress and immunogenic cell death. Cytokine and Growth Factor Reviews, 2013, 24, 311-318.	7.2	177
41	Trial watch. OncoImmunology, 2013, 2, e23803.	4.6	92
42	Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle, 2013, 12, 647-654.	2.6	16
43	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. OncoImmunology, 2013, 2, e22409.	4.6	20
44	Cisplatin Resistance Associated with PARP Hyperactivation. Cancer Research, 2013, 73, 2271-2280.	0.9	143
45	Analgesic, Anti-Inflammatory and Anticancer Activities of Extra Virgin Olive Oil. Journal of Lipids, 2013, 2013, 1-7.	4.8	32
46	Immunosurveillance against tetraploidization-induced colon tumorigenesis. Cell Cycle, 2013, 12, 473-479.	2.6	36
47	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle, 2013, 12, 417-421.	2.6	26
48	Trial watch. OncoImmunology, 2013, 2, e23510.	4.6	153
49	Immunostimulatory activity of lifespan-extending agents. Aging, 2013, 5, 793-801.	3.1	27
50	Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle, 2012, 11, 3472-3480.	2.6	32
51	Tetraploid cancer cell precursors in ovarian carcinoma. Cell Cycle, 2012, 11, 3157-3158.	2.6	6
52	Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity. Molecular Cell, 2012, 48, 667-680.	9.7	239
53	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	6.4	122
54	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 1472.	6.4	0

#	Article	IF	Citations
55	Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle, 2012, 11, 2149-2158.	2.6	34
56	The secret ally: immunostimulation by anticancer drugs. Nature Reviews Drug Discovery, 2012, 11, 215-233.	46.4	591
57	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. Science, 2012, 337, 1678-1684.	12.6	367
58	Trial watch. OncoImmunology, 2012, 1, 1111-1134.	4.6	152
59	Trial watch. OncoImmunology, 2012, 1, 1323-1343.	4.6	203
60	Selective killing of p53â€deficient cancer cells by SP600125. EMBO Molecular Medicine, 2012, 4, 500-514.	6.9	47
61	Autophagic removal of micronuclei. Cell Cycle, 2012, 11, 170-176.	2.6	162
62	Immunosurveillance against cancer-associated hyperploidy. Oncotarget, 2012, 3, 1270-1271.	1.8	10
63	Cytofluorometric Purification of Diploid and Tetraploid Cancer Cells. Methods in Molecular Biology, 2011, 761, 47-63.	0.9	5
64	IKK connects autophagy to major stress pathways. Autophagy, 2010, 6, 189-191.	9.1	46
65	The IKK complex contributes to the induction of autophagy. EMBO Journal, 2010, 29, 619-631.	7.8	274
66	Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO Journal, 2010, 29, 1272-1284.	7.8	155
67	Surfaceâ€exposed calreticulin in the interaction between dying cells and phagocytes. Annals of the New York Academy of Sciences, 2010, 1209, 77-82.	3.8	97
68	miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death. Cancer Research, 2010, 70, 1793-1803.	0.9	262
69	Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway. Clinical Cancer Research, 2010, 16, 3100-3104.	7.0	325
70	Involvement of p38Î± in the mitotic progression ofp53^{-/-}tetraploid cells. Cell Cycle, 2010, 9, 2895-2901.	2.6	8
71	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. Cell Cycle, 2010, 9, 2902-2907.	2.6	5
72	Chemotherapy induces ATP release from tumor cells. Cell Cycle, 2009, 8, 3723-3728.	2.6	233

#	Article	IF	Citations
73	Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. Cell Cycle, 2009, 8, 1030-1035.	2.6	40
74	p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. Cell Cycle, 2009, 8, 1380-1385.	2.6	38
75	Viral subversion of immunogenic cell death. Cell Cycle, 2009, 8, 860-869.	2.6	60
76	Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 364-375.	4.9	185
77	Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle, 2008, 7, 1956-1961.	2.6	41
78	Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone. Cancer Research, 2008, 68, 5301-5308.	0.9	101
79	Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway. PLoS ONE, 2007, 2, e1337.	2.5	67
80	Cell proliferation depends on mitochondrial Ca2+uptake: inhibition by salicylate. Journal of Physiology, 2006, 571, 57-73.	2.9	74